IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Systematic Review On Moxifloxacin And It's Use Of Manage Of Bacterial Infection.

Ms. Mohini Rajendra Yele., Ms.Maheshwari SantoshPomane,

Ms. Jasmin Kamal Mulani., Ms.Akanksha Anand Doifode

Ms. Anuradha Sanjay Gaikwad., Ms.Siddhi Bharat Sartape,

Ms.Komal Hole

Institute of pharmaceutical science and research(for gils)(college code-6914)pune-solapur Highway, Swami chincholi (Bhigwan), Tal-Daund Dist-Pune 413130

Abstract:

Fluroquinolone antibiotic moxifloxacin is used to treat a variety of bacterial illness. A brand-new fluroquinolone antibiotic, moxifloxacin has a wide rang of activity against both Gram-positiveand Gram-negative

bacteria. when compared to ciprofloxacin, it exhibits better activity against Gram-positive species (such as staphylococci, steptococci,and enterococci) and anarobes, including penicillin-resistant sreptococcus pneumoniae. review of moxifloxacin activities, pharmaceutical kinetic, pharmacodynamics, efficacy, safety, medication interaction, dose, and administration

A fluoroquinolone antibiotic called moxifloxacin is used to treat infection such as pneumonia, conjunctivitis, endocarditis, tuberculosis, sinusitis, the respiratory system, pelvic inflammatory disease, the skin and the intra-abdominal activity. Although most studies of its safety profile are good, others have quetioned iit because of infrequent but ptentially deadly toxicity (such as hepatic, cardiac, or cutaneous responses). Acute exacerbations of community-acquired pneumonia caused by pneumococcal (CAP) were observed in studies performed in patients

Keywords:

Moxifloxacin, Fluoroquinolone, Anti-bacterial agent, Gram-positive-negative, Analysis, Pneumonia, sinusitis,Tuberculosis

Introduction:

In 1999, the United States approved the use of doxifloxacin, a fourth-generation fluoroquinolone antibiotic (Soto et al., 2002). It is frequently used to treat bacterial infections, including pneumonia, conjunctivitis, endocarditis, tuberculosis, and sinusitis. It is included in the World Health Organization's List of Essential Medicines. An antibiotic with a broad that works against both Gram-positive and Gram-negative bacteria is doxifloxacin. By preventing bacterial DNA topoisomerases from functioning, moxifloxacin, like other fluoroquinolone antibacterial medicines, stops the growth of sensitive bacteria.It can be administered as an eye drop, by infusion into a vein, or by mouth.Moxifloxacin's antibacterial action is wide-ranging.including action against Streptococcus pneumoniae,a bacteria resistant to penicillin. In many different areas of the body, bacterial infections are treated with roxifloxacin. Additionally, plague (which involves pneumonic and septicemic a plague) is treated and prevented using it. It functions by eradicating the infection-causing germs.The group of drugs called quinolone antibiotics includes moxifloxacin. It functions by eradicating

bacteria or stopping their growth.Since a once-daily 400 mg antibacterial for the treatment of infections of the respiratory tract (community-acquired the illness [CAP], acute symptoms of chronic asthma [AECB], and severe bacterial sinusitis [ABS]), roxifloxacin is authorised for oral and via IV in 123 and 108 nations respectively. It is also approved for the treatment of pelvic inflammatory disorder [PID], complex and uncomplicated skin and tissue structure infections.It has received an estimated 140 million medications worldwide, and for each of these indications, guidelines and/or recommendations include it as an efficient substitute.However, this medication won't help with the flu, the common cold, or other viral infections.

Only a prescription from your doctor is required to purchase thismedication.

Chemical structure:

2D structure of moxifloxacin



3D structure of moxifloxacin



Name: Difluorochinolina
CAS # : 112811-72-0
Molecular Formula: $C_{14}H_{11}F_2NO_4$
Formula Weight: 295.24

(V)

Name: DABCN
CAS # : 151213-40-0
Molecular Formula: $C_7H_{14}N_2$
Formula Weight: 126.20

(VI)

Name: Moxifloxacina Base
CAS # : 151096-09-2
Molecular Formula: $C_{21}H_{24}FN_3O_4$
Formula Weight: 401.43

(II)

Name: Moxifloxacina HOTs
CAS # : _
Molecular Formula: $C_{21}H_{24}FN_3O_4$
Formula Weight: 573.63

(IV, R=p-MePh)

Name: Moxifloxacina HCl
CAS # : 186826-86-8
Molecular Formula: $C_{21}H_{24}FN_3O_4$
Formula Weight: 437.89

(I)

Synthesis of moxifloxacin:



Chemical properties:

- Melting temperature - 324-325^{O}C
- Boiling temprature - 636.4^{O}C
- Density - 1.409
- Refractive index - 1.633
- Storage condition - Stored in cool & dry place(2-8^{O}C).
- Color - slightly yellow to yellow powder.
- Solubility - soluble in water.
- Appearance - almost white to yellowish crystalline powder
- Percent purity - 98%-102%
- Wavelength - 287nm and 317.9nm

Physical properties:

- IUPAC name - 1-Cyclopropyl-7-[(1s,6s)-2,8-diazabicyclo[4.3.0]nonan-8-yl]-6 -fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid.
- Molecular weight - 401.4g/mol
- Molecular formula - $C_{21}H_{24}FN_3O_4$
- Synonyms - Moxifloxacin, Moxifloxacino
- Brand name - Actura, Avalox, Avelox, Octegra,Proflox
- Routes of adminidtration - By mouth, intravenous, eyedrops.
- Drug class - Antibiotic(fluroquinolon)

Uses:

Infections of the respiratory tract, inflammation, anthrax infection, intra-abdominal diseases, endocarditis, pneumonia, and tuberculosis are among the conditions that moxifloxacin addresses.

Rapid bacterial sinus infections, acute bacterial aggravation of chronic lung disease, community-acquired pneumonia, complex and easy diseases of the skin as well as the tissue structure, and difficult intra-abdominal diseases are among the conditions that moxifloxacin is approved to treat in the United States. It has approval in the European Union to treat acute bacterial sinusitis, non-severe pneumonia from the community, and acute bacterial complications of chronic bronchitis.

Background:

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Formulation of moxifloxacin:

FOR injection:

Procesure: The osmolality of moxifloxacine VIOSER a total of 400mg/250 a millilitre are 270—320 mOsm/kg, and the pH ranges from
4.4 to 4.6. Each 250 ml bottle of moxifloxacin (as hydrochloride)contains 400 mg. There is 1.745 mg of moxifloxacin (as
hydrochloride) in each millilitre. Bottles made of low-densitypolyethylene are used to pack the solution

For tablet:

Procesure: A partially granulating mixture was created by combining Lactose and Compound-I in a Shizona mixer. Purified water was added to this partially granulating mixture and granulated until a coagulate mass was achieved. Granules were collected and dried. Following a screening process, the dried granules were combined with lactose(234.60mg), croscarmellosesodium(23mg) , colloidal silicon dioxide(2mg) , and magnesium stearate(4.mg) in a blender and left for ten minutes. To create tablets, the mixture was subsequently compressed using a machine.

In a coating pan, hydroxypropyl cellulose and colouring chemicals such as carbon monoxide & yellow oxide of iron were applied to thecores.

For opthalmic solution:

Procesure: It has a pH of 6.8, which is almost neutral, and is isotonic without any preservatives. Boric acid, 5 mg/mL (0.5%) moxifloxacin, and filtered water make up Vigamox's composition. Among the already approved topical antibiotics, it is distinct due tothe absence of the preservation BAK (benzalkonium chloride).

Overdose:

"If an acute overdose occurs, it is important to keep yourself properly hydrated and to empty your stomach. It is advised to monitor your ECG since QT interval prolongation may occur. The patient needs to get supportive care and close observation.
Activated charcoal may be administered as soon as feasible following an oral overdose to avoid an excessive rise in systemic moxifloxacin exposure. Constant continuous dialysis through the peritoneum and hemodialysis remove between 3% to 9% of the dosage of moxifloxacin along with 2% to 4.5% of its lactic acid metabolite, respectively."

Toxicity:

CNS and gastrointestinal side symptoms, such as reduced activity,sleepiness, trembling, convulsions, vomiting, and diarrhoea, are signs of an overdose. In rats and mice, a minimal lethal iv dose is 100 mg/kg.

Pharmacology:

Registance: All quinolones exhibit resistance that is mediated by either modifications to the targeted site (DNA, which is gyrase and/or enzyme IV) or modifications that affect the intracellular drugaccumulation (i.e., greater efflux).

MOA of moxifloxacin:

By inhibiting the enzymes topoisomerase (DNA gyrase) & topoisomerase IV, moxifloxacin has bactericidal effects. An important enzyme called DNA gyrase play a role in the transcription, replication, as well as correction of bacterial DNA. During bacterial cell division, the enzyme topoisomerase IV is recognised to be crucial for the partitioning of chromosomal DNA.



Antibacterial activity:

An extended-spectrum fluoroquinolone with an antibacterial spectrum that encompasses all common respiratory tract infections is doxifloxacin. Among the most effective fluoroquinolones versus S. pneumoniae (average weighted MIC90<0.3 mg/L), it can effectively combat bacteria that are resistant to both macrolides and penicillins.Additionally, it has variable action towards methicillin-resistant Staphylococcus aureus (MIC90 2 to 8 mg/L) or borderline action against ciprofloxacin-resistant strains at S. aureus (MIC90 1 to 2 mg/L). It is also operating opposed to S. pyogenes and streptococciin the group A (mean weighted MIC90 0.24 mg/L) as well as methicillin-susceptible S. aureus strains (mean balanced MIC90
0.10 mg/L).

Pharmacokinetics:

By conjugating glucuronide and sulphate, approximately 52 percentof an oral or iv dose of this antibiotic is metabolised. Oxifloxacin does not influence or participate in the metabolism of the cytochrome P450 system. About 38% with the dose is made up of the sulphate conjugate (M1), which is mostly excreted in faeces. An

oral or iv dose is transformed to a glucose conjugate (M2), that is only eliminated in the urine, in about 14% of cases. While M1 plasma concentrations are typically less than 10% of moxifloxacin plasma concentrations, peak M2 plasma concentrations are approximately 40% of the parent drug's.

Parmacodynamics:

One type of quinolone/fluoroquinolone antibiotic is doxifloxacin. The following bacteria can cause infections that can be treated withdoxifloxacin: The following are examples of aerobic Gram-positive microorganisms: Streptococcus pneumoniae, Micrococcus luteus, Corynebacterium species, staph aureus, staphylococcus haemolyticus, the bacterium St hominis, and Staphylococcus warneri. Haemophilus influenzae, Haemophilus parainfluenzae, and Acinetobacter lwoffii are examples of aerobic Gram-negative microbes. Additional microbes: Chlamydia trachomatis. By connecting itself to the enzyme DNA gyrase, which permits the untwisting necessary to copy a single double helix of into two, doxifloxacin, a bactericidal agent, inhibits the replication of bacterial DNA. The medication notably exhibits a 100-fold a greater bond for microbial DNA enzyme gyrase than for human DNA gyrase. A antibiotic with a wide spectrum that works against both the two types of bacteria is doxifloxacin.

Drug interaction:

Similar to other fluoroquinolones, co-administration of an antacid, sucralfate, or an iron preparation significantly decreases the bioavailability of moxifloxacin. Concurrent administration of supplements containing calcium slows down the pace of absorption, but does not change the amount of moxifloxacin absorption.

Unlike certain other drugs in this family, doxifloxacin is notcompatible through a medication such as β-acetyldigoxin, probenecid, ranitidine, warfarin, or oral contraceptives.

Conclusion:

The advantages of moxifloxacin, an extended-spectrum fluoroquinolone, are its once-daily dosing, reduced risk of medication interactions, and strong effectiveness against pneumococci. The available data indicate that moxifloxacin could be to develop into the primary choice for the therapy of community-acquired infections of the lower respiratory tract,
especially in areas where resistant to drugs S. pneumoniae and H. influenzae isolates are typical. However, studies about its toleratedto at-risk patients with a prolonged QT interval are needed.

References:

1) Lode H, Garau J. Improving care for patients with respiratorytract infections. J Chemother 2002 Feb; 14 Suppl. 2: 22-8

2) Adams SG, Anzueto A. Antibiotic therapy in acute exacerbationsof chronic bronchitis. Semin Respir Infect 2000; 15(3): 234—47

3) Andriole VT. Overview of the fluoroquinolones: focus onmoxifloxacin. Hosp Formul 2002; 37 Suppl. 3:13-5

4) Barman Balfour JA, Lamb HM. Moxifloxacin: a review of itsclinical potential in the management of community-acquired respiratory tract infections. Drugs 2000 Jan; 59(1): 115-39

5) Muijsers RB, Jarvis B. Moxifloxacin in uncomplicated skin andskin structure infections. Drugs 2002; 62(6): 967—73; discussion974-5

6) Dalhoff A. Dissociated resistance among fluoroquinolones[abstract]. Anti-Infect Drug Chemother 1998; 16 Suppl. 1: 75

7) Bearden DT, Danziger LH. Mechanism of action of and resistance to quinolones.

Pharmacotherapy 2001; 21 (10 Suppl. II):224S—32S

8) Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE,Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR:

Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 1;37(11):1448-52. Epub2003 Nov 4. [Article]

9) Abshire R, Cockrum P, et al. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment. Clin Ther. 2004;26:191—6. [PubMed] [Google Scholar]

10) Alexandrakis G, Alfonso EC, et al. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497—502. [PubMed][Google Scholar]

11) Alfonso E, Crider J. Ophthalmic infections and their
anti-infective challenges. Surv Ophthalmol. 2005;50(Suppl 1):S1—
6. [PubMed] [Google Scholar]

12) Allen GP, Kaatz GW, et al. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents. 2004;24:150—
60. [PubMed] [Google Scholar]

13) Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials:past, present and future perspectives. Int J Antimicrob Agents. 2000;16:5—15. [PubMed] [Google Scholar]

14) Ball P, Fernald A, et al. Therapeutic advances of new fluoroquinolones. Expert Opin Investig Drugs. 1998;7:761—83.[PubMed] [Google Scholar]

15) Ball P, Stahlmann R, et al. Safety profile of oral and intravenousmoxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther. 2004;26:940—50. [PubMed] [Google Scholar]

16) Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther. 1999;21:3—40. discussion 1
—2. [PubMed] [Google Scholar]

17) Blondeau JM. A review of the comparative in-vitro activities of12 antimicrobial agents, with a focus on five new respiratory

quinolones. J Antimicrob Chemother. 1999;43(Suppl B):1—11.[PubMed] [Google Scholar]

18) Burka JM, Bower KS, et al. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healingfollowing photorefractive keratectomy. Am J Ophthalmol. 2005;140:83—7. [PubMed] [Google Scholar]

19) Baranowski, P., Karolewicz, B., et al. (2014). Ophthalmic DrugDosage Forms: Characterization and Research Methods. The Scientific World Journal, 1-15. Retrieved from: https://www.hindawi.com/journals/tswj/2014/861904/

20) Future Market Insights. (2020). Ophthalmic Eye Drops Market.Retrieved from: https://www.futuremarketinsights.com/reports/ophthalmic-eye-drops-market#

21) Bayer Corporation. Avelox™ (moxifloxacin hydrochloride)tablets prescribing information. West Haven (CT), 1999

22) Woodcock JM, Andrews JM, Boswell FJ. In vitro activity of BAY12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997 Jan; 41: 101—6

23) Wise R. A review of the clinical pharmacology of moxifloxacin, anew 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest 1999 May; 17: 365—87

24) Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines formanagement. Clin Infect Dis 1998 Apr; 26: 811—38

25) Garcia-Saenz MC, Arias-Puente A, et al. Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin. JCataract Refract Surg. 2001;27:1969–74.

26) Goldstein MH, Kowalski RP, et al. Emerging fluoroquinolone resistance in bacterial keratitis:a 5-year review. Ophthalmology.1999;106:1313–8